



# The Integrated Medical Model

## Statistical Forecasting of Risks to Crew Health and Mission Success

M.A. Fitts<sup>1</sup>, E. Kerstman<sup>2</sup>, D.J. Butler<sup>3</sup>, M.E. Walton<sup>4</sup>, C.G. Minard<sup>5</sup>, L.G. Saile<sup>6</sup>, S. Toy<sup>7</sup>, J. Muniz<sup>8</sup>

<sup>1</sup>NASA Johnson Space Center, <sup>2</sup>University of Texas Medical Branch - Galveston, <sup>3,4,5,6</sup>Wyle, <sup>7</sup>Muniz, <sup>8</sup>NASA Johnson Space Center

03:52:13+00:00Z

Research Center

erred, continuous effort. Data is initially viewed by Space Medicine Subject Clinical Reviewers. This validation of the tasks and resources required to

rently a three-phased effort. Phase I been assigned to all model assumptions. alues. And Phase III compares if available.

IMM is operating properly, the IMM is kelled per the ClIFF. The Clinical Lead nalyises to identify and resolve

owever only a few conditions have is so the following forecasts are offered ts 10,000 mission simulations, with one rew tall).

6-Month Mission with no medical capabilities. Since no conditions were treated, the actual mission outcome (green) is equal to the untreated scenario (blue). Mission Goal Point (red) reflects outcomes if resources were unlimited and treatments were 100% effective.

6-Month Mission with medical capabilities shows a strong shift toward a higher probability of mission success.

3-year Mission with medical capabilities. Performance clearly shows the bimodal distribution associated by modeling a worst case and best case clinical outcome.

B) Sensitivity analysis reveals nasal congestion is the most influential variable determining how many disorders occur.

A) 6-month Mission forecast of total number of medical disorders (assuming universe of 37 conditions).

uracies

nt of view of the mission debrief. This already completed. What happened went with tracking each day and o be very complex and not very helpful nt limitations.

ate. The only exception are recurrent . All outcomes are calculated as if they in summed together. This causes a

to refine the clinical evidence base, and ions for medical systems and program. The IMM Project coordinates ver Risk Management efforts such as sement and Integration Team (RAIT), of Astronaut Health (LSAH) Office.

provided by NASA Technical Reports Server


brought to you by CORE

### Overview

The Integrated Medical Model (IMM) helps capture and use organizational knowledge across the space medicine, training, operations, engineering, and research domains. The IMM uses this domain knowledge in the context of a mission and crew profile to forecast crew health and mission success risks. The IMM is most helpful in comparing the risk of two or more mission profiles, not as a tool for predicting absolute risk. The process of building the IMM adheres to Probability Risk Assessment (PRA) techniques described in NASA Procedural Requirement (NPR) 8705.5, and uses current evidence-based information to establish a defensible position for making decisions that help ensure crew health and mission success. The IMM quantitatively describes the following input parameters:


- medical conditions and likelihood,
- mission duration,
- vehicle environment,
- crew attributes (e.g. age, sex)
- crew activities (e.g. EVA's, Lunar excursions),
- diagnosis and treatment protocols (e.g. medical equipment, consumables pharmaceuticals), and
- Crew Medical Officer (CMO) training effectiveness.

It is worth reiterating that the IMM uses the data sets above as *inputs*. Many other risk management efforts stop at determining only likelihood. **The IMM is unique in that it models not only likelihood, but risk mitigations, as well as subsequent clinical outcomes based on those mitigations.** Once the mathematical relationships among the above parameters are established, the IMM uses a Monte Carlo simulation technique (a random sampling of the inputs as described by their statistical distribution) to determine the probable outcomes. Because the IMM is a stochastic model (i.e. the input parameters are represented by various statistical distributions depending on the data type), when the "mission" is simulated 10-50,000 times with a given set of medical capabilities (risk mitigations), a prediction of the most probable outcomes can be generated. For each "mission", the IMM tracks which conditions occurred and decrements the pharmaceuticals and supplies required to diagnose and treat these medical conditions. If supplies are depleted, then the medical condition goes untreated, and crew and mission risk increase. The IMM currently models approximately 30 medical conditions. By the end of FY2008, the IMM will be modeling over 100 medical conditions, approximately 60 of which have been recorded to have occurred during short and long space missions.



### IMM Capabilities

- Simultaneously assesses ALL parameters that influence medical risk in the context of a mission and crew profile. Other risk efforts typically examine one medical condition at a time (e.g. by using the 5x5 risk matrix),
- Evaluates mission risk by modeling all three risk components (likelihood, available mitigation strategy, and consequence). Many risk efforts stop once an estimation of likelihood is characterized,
- Uses Monte Carlo simulation to forecast the most likely outcomes for a mission and crew profile
- Offers optional optimization of the contents of a crew health care system
- Aids operational and research decisions based on risk, mission or crew attributes, or medical system mass and volume
- Provides various analysis capabilities (e.g. sensitivity analyses, spider charts, and tornado charts) to identify key contributors that influence clinical outcomes, mission success, and enterprise budgets. By identifying contributors that are most influential to risk, organizational resources can be focused on the efforts that matter most
- Accounts for *uncertainty* in both the model inputs and outputs, and
- Characterizes the level and duration of impairment of a crew member by using a utility measure (i.e. % whole body impairment; also termed "functional impairment") currently used by the American Medical Association (AMA) and the medical insurance industry



### Methods

- Establishing a List of Relevant Medical Conditions** – A baseline list of medical conditions serves as the IMM clinical modelling roadmap and is required to manage the scope of the project. The current Baseline List of Medical Conditions (BLMC) – derived from the ISS Medical Checklist – covers approximately 75 conditions, most of which have occurred during past space flights. The ISS Checklist was used as a starting point; the BLMC will be supplemented with new data from the Longitudinal Study of Astronaut Health (LSAH) Database, Delphi Study, and space medicine peer reviews.

- Establishing incidence rates** – The IMM incidence rate (defined as events/person-year) for each condition on the BLMC was initially established from reviewing historical medical event records from the Apollo, Skylab, Shuttle, Mir, and ISS Programs. Additional incidence data was derived by conducting brief literature reviews and queries to the LSAH Database. The in-flight incidence data will be updated with terrestrial surrogate population data as applicable; a collaboration with the United States Army Aeromedical Research Laboratory is underway.

- To gain greater insight of operations or risk factors, some medical conditions such as bone fracture, renal stone formation, behavioural health have stochastic predictive models developed to forecast incidence forms. These forecasted distributions are then used in the IMM as inputs.

- Clinical Findings Form (ClIFF): Quantifying clinical information for each condition** - The ClIFF serves as both a clinical requirements document (for the development of the IMM) and reference document for each medical condition modeled in the IMM. The ClIFF provides a framework for the clinician to capture clinical and operational data in a quantified form needed by the IMM. The quantified data (either deterministic or stochastic), assumptions, and sourced references provide a defensible position for accepting risk and making financial investments in areas where little information exists. The table below is an excerpt from the ClIFF for corneal abrasion:

TREATMENT OPTIONS	Table of Treatments and Outcomes					
	Diagnosis & Initial Treatment	Treatment/ Convalescence		Recovered/ Mission End State		
	FI* (%)	Duration (hrs)	FI (%)	Duration (hrs)	FI (%)	Mission End state results**
ISS-based Treatment (best case scenario): A1=0-99%	100	0.5-0.75	16-24 <sup>2</sup>	24-48	0	N/A
ISS-based Treatment (worst case scenario): A2=1-10%	100	0.75-1.5	16-24 <sup>2</sup>	336	23.3-24.5 <sup>2</sup>	EVAC (0-2%)
Untreated Case	N/A	N/A	10.8-35 <sup>3</sup>	>336	10.8-35 <sup>3</sup>	EVAC (0-100%)

- Resource Table; Quantifying the items needed to diagnose and treat each condition** – For each medical condition, the tasks and items needed to diagnose and treat the disorder are recorded. For each medical item, the quantity required, unit mass, and unit volume are tracked for both a best-case and worst-case treatment scenario. Eventually, tasks and items required to provide the best urban care will be included in the IMM to enable comparisons with terrestrial standards and establish a metric for clinical effectiveness.

- Establishing Metrics for Crew Health Risk** – Adopted from AMA guidelines, the Quality Adjusted Life Years (QALY) lost metric accounts for the final functional impairment of the individual based on available mitigation strategies and life expectancy. All things equal, health risks (a.k.a. QALY lost) will be greater for younger individuals since they have more quality years to lose due to their longer life expectancy.

- Establishing Metrics for Mission Risk resulting from crew health disorders** – Mission risk is done by scaling the lost QALY's to the duration of the mission instead of expected life span.

### Validation


- Clinical** – Clinical validation vetted by the IMM Clinical Matter Advisors, and final process would also assess diagnose and treat each
- Statistical** – Statistical validation ensures the correct distribution Phase II tests the model v predicted forecasts with e
- Architecture/Design** – T tested after medical cond reviews IMM forecasts an inconsistencies early.

### IMM Output - Ex

The IMM currently models 3 assigned diagnosis and treat as examples only. Each for male and one female crew m



6-Month Mission with medical capabilities shows a strong shift toward a higher probability of mission success.



A) 6-month Mission forecast of total number of medical disorders (assuming universe of 37 conditions).

### Key Assumption

- The IMM views the mission is view means the mission is not tracked on which day is not track building a mission log, but at the time. This choice le
- All medical events are cor disorders that depend on were the only impact on it higher QALY lost.

### Summary

The IMM will continue to add is on track to help support ris operational concepts for the data mining and modeling ac the Exploration Medicine Ele SD2/Delphi Study, and Long



# The Integrated Medical Model (IMM) Project

---

- Overview – Statistical decision support tool for forecasting crew health and related mission risks, and optimizing the medical logistics “footprint” of in-flight crew medical systems
- Progress to Date
  - Established Baseline list of approximately 75 conditions
  - 37 medical conditions modeled
  - Defined Risk Metrics for crew and mission
  - Established Clinical Finding Form Template
  - Developed Resource Manager Software to track medical consumables
  - Compiled historical Review of Medical Events
  - Populating Resource Tables with unit quantity, mass, and volume  
Collaborating with USAARL to refine incident data with surrogate population data
  - Developing Clinical and Statistical Validations Plans

# IMM Key Milestones



FY2008	FY2009	FY2010	Capabilities
<ul style="list-style-type: none"> <li>Δ Baseline Medical Conditions List                             <ul style="list-style-type: none"> <li>Δ Complete CLIFF's (72+ conditions)                                     <ul style="list-style-type: none"> <li>Δ Model 72+ Conditions   <ul style="list-style-type: none"> <li>Δ Integrate Resource Table (72+ conditions x2)</li> </ul> </li> <li>Δ Establish Statistical/Clinical Validation Plans   <ul style="list-style-type: none"> <li>Δ Assess/Integrate USAARL data</li> </ul> </li> </ul> </li> </ul> </li> </ul>			<ul style="list-style-type: none"> <li>✓ Initial roadmap established</li> <li>✓ Outcomes mapped to conditions and treatments</li> <li>✓ Initial assessments capable</li> <li>✓ Logistics mapped to risks</li> <li>✓ Baseline conditions list expanded via surrogate population data</li> </ul>
	<ul style="list-style-type: none"> <li>Δ Incorporate Delphi Data (when available)</li> <li>Δ Develop Database Integration Requirements</li> <li>Δ Refine Loss of Mission (LOM) metric                             <ul style="list-style-type: none"> <li>Δ Initiate Statistical/Clinical Validation Plans                                     <ul style="list-style-type: none"> <li>Δ Migrate CLIFF's to database</li> </ul> </li> </ul> </li> <li>Δ 100+ conditions modeled (est.)</li> </ul>		<ul style="list-style-type: none"> <li>✓ Baseline conditions list +</li> <li>✓ Ensure knowledge capture</li> <li>✓ Refined comparative mission risk assessments</li> <li>✓ Efficient, current modeling</li> <li>✓ Prep. for database integration</li> <li>✓ Increased confidence levels</li> </ul>
		<ul style="list-style-type: none"> <li>Δ Complete Initial Validation                             <ul style="list-style-type: none"> <li>Δ Expand Risk Factors                                     <ul style="list-style-type: none"> <li>Δ Database Integration</li> </ul> </li> </ul> </li> <li>Δ 120+ conditions modeled</li> </ul>	<ul style="list-style-type: none"> <li>✓ Validated planning tool</li> <li>✓ Increased crew/mission modeling fidelity</li> <li>✓ Efficient, current modeling with HITT/PCDB</li> <li>✓ Increased confidence levels</li> </ul>